Kura Oncology (KURA) News
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
6.91-0.44 (-5.99%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KURA news summary
We found 11 recent headlines mentioning Kura Oncology (KURA): 1 in the past week and 11 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. KURA is making an outsized move today, down 5.99% at $6.91, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Tuesday 11/17 Insider Buying Report: KURA, IOND", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Kura Oncology headlines
- Tuesday 11/17 Insider Buying Report: KURA, IONDBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their…NasdaqKURA, IOND
- Kura Oncology to Participate in Two Investor Conferences in NovemberSAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that…GlobeNewswire
- Kura Oncology Reports Q3 Results; KOMZIFTI Revenue Grows 53%, Advances 2027 Pipeline Plans(RTTNews) - Wednesday, Kura Oncology, Inc. (KURA) reported third-quarter 2026 financial results, with KOMZIFTI net product revenue increasing 53% sequentially to $13.9 million. The company also…NasdaqKURA, BF.A
- Kura Oncology (KURA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Kura Oncology GAAP EPS of -$0.78 beats by $0.05, revenue of $22.84M misses by $1.05MSeeking Alpha
- Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update– KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% –GlobeNewswire
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today…GlobeNewswire
- Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –GlobeNewswire
- Kura Oncology to Report Third Quarter Financial Results on November 10SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report…GlobeNewswire
- Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseQiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqQGEN, KURA
- Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should KnowKura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqKURA, INSM